2. Sensitivity analysis: non‐replicating viral vector vaccine .
| Developer – comparison | Analysesa | Outcomes | ||||||
| SARS‐CoV‐2 infection | Symptomatic COVID‐19 | Severe COVID‐19 | All‐cause mortality | SAEs | Systemic reactogenicity events | AEs | ||
|
VE (95% CI) No. of trials (No. of participants) |
RR (95% CI) No. of trials (No. of participants) |
|||||||
| ChAdOx1 – AstraZeneca + University of Oxford versus placebo | Main analysis | 59.35% (48.00% to 68.22%) 5 RCTs (43,390) |
70.23% (62.10% to 76.62%) 5 RCTs (43,390) |
— | 0.48 (0.20 to 1.14) 5 RCTs (56,726) |
0.88 (0.72 to 1.07) 7 RCTs (58,182) |
3.93 (2.11 to 7.29) 1 RCT (256) |
Not pooled |
| Sensitivity 1 | — | — | — | 0.50 (0.20 to 1.21) 5 RCTs (56,873) |
0.86 (0.70 to 1.06) 7 RCTs (58,329) |
— | — | |
| Sensitivity 2 | — | — | — | 0.48 (0.20 to 1.14) 5 RCTs (56,623) |
0.88 (0.72 to 1.08) 6 RCTs (57,823) |
— | — | |
| Sensitivity 3 | — | — | — | 0.50 (0.20 to 1.21) 5 RCTs (56,623) |
0.86 (0.70 to 1.05) 6 RCTs (56,879) |
— | — | |
| Ad26.COV2.S – Janssen Pharmaceutical Companies versus placebo | Main analysis | — | 66.90% (59.10% to 73.40%) 1 RCT (39,058) |
76.30% (57.90% to 87.50%) 1 RCT (39,058) |
0.25 (0.09 to 0.67) 1 RCT (43,783) |
0.92 (0.69 to 1.22) 1 RCT (43,783) |
1.83 (1.29 to 2.60) 2 RCTs (7222) |
1.57 (0.75 to 3.29) 2 RCTs (7222) |
| Sensitivity 1 | — | — | — | 0.25 (0.09 to 0.67) 1 RCT (44,325) |
0.92 (0.69 to 1.22) 1 RCT (44,325) |
1.83 (1.27 to 2.63) 2 RCTs (44,813) |
1.57 (0.74 to 3.32) 2 RCTs (44,813) |
|
| Sensitivity 2 | — | — | — | — | — | — | 1.09 (0.96 to 1.24) 1 RCT (6736) |
|
| Sensitivity 3 | — | — | — | — | — | — | — | |
| Gam‐COVID‐Vac – Gamaleya Research Institute (Sputnik V) Gam‐COVID‐Vac versus placebo | Main analysis | — | 91.10% (83.80% to 95.10%) 1 RCT (18,695) |
100.00% (94.40% to 100.00%) 1 RCT (19,866) |
0.99 (0.10 to 9.54) 1 RCT (21,862) |
0.65 (0.39 to 1.07) 1 RCT (21,862) |
— | — |
| Sensitivity 1 | — | — | — | 1.00 (0.10 to 9.57) 1 RCT (21,977) |
0.65 (0.39 to 1.07) 1 RCT (21,977) |
— | — | |
| Sensitivity 2 | — | — | — | — | — | — | — | |
| Sensitivity 3 | — | — | — | — | — | — | — | |
| AE: adverse event; CI: confidence interval; COVID‐19: coronavirus disease 2019; RCT: randomized controlled trial; RR: risk ratio; SAE: serious adverse event; SARS‐CoV‐2: severe acute respiratory syndrome coronavirus 2; VE: vaccine efficacy. | ||||||||
aSensitivity 1: participants randomized; Sensitivity 2: early‐phase studies excluded; Sensitivity 3: only published studies.